



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 28 Mei 2018 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices:

- [NIH releases strategic plan for data science](#)
- [HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains](#)
- [Biomedical researchers are stressed by a hypercompetitive environment that's particularly destructive for early- and mid-career investigators.](#)
- Review [information for foreign grants](#) from the NIH Office of Extramural Research (OER)
- [Top Priority for FY 2018 Awards: Update Inclusion Enrollment Records in IMS by June 8](#)

1. Future Leaders – African Independent Researchers (FLAIR) Fellowships

Letter of Intent: 30 days prior to the application due date

Hyperlink:

<https://www.aasciences.ac.ke/aesa/en/programmes/flair/>

Type:

Application Due Date: 3.00 pm UK time on Wednesday 20 June 2018.

Funding Opportunity Announcement: FLAIR Fellowships are for talented African early career researchers who have the potential to become leaders in their field. Applications should be within the remit of natural sciences and medical research (excluding clinical and patient-orientated research). These fellowships provide the opportunity to build an independent research career in a sub-Saharan African institution and to undertake cutting-edge scientific research that will address global challenges facing developing countries. Each FLAIR Fellowship will be for two years initially and will offer up to £150,000 per year, alongside a programme of support to develop fellows as independent research leaders including training and mentoring, and opportunities to network both regionally and with the UK and to develop international collaborations. This is a partnership between the [African Academy of Sciences \(AAS\)](#) and the Royal Society, supported by the [Global Challenges Research Fund \(GCRF\)](#). Applicants are encouraged to familiarise themselves with the GCRF research agenda and Global Sustainable Development Goals to ensure that their research aligns within the remit of these programmes.

The objectives of this scheme are to:

- Support talented early career researchers to establish an independent research career in African institutions.
- Enable high-quality research that addresses the global development challenges faced by the African continent.
- Provide world-class support, training, mentoring and networking opportunities to benefit early career African researchers.

You can apply for this scheme if you:

- Are a national of a sub-Saharan African country and wish to work in a sub-Saharan African country in a research position, or a national of a sub-Saharan African country in the diaspora and wish to return to a sub-Saharan African research position.
- Hold a PhD by the time you apply.
- Are an early career researcher and have no more than 10 years of research experience since completing your PhD by the time of application.

Budget: two years initially and up to £150,000 per year

2. B-Cell Epitope Discovery and Mechanisms of Antibody Protection

Letter of Intent: Contract Specialist phamm@exchange.nih.gov

Hyperlink: [BAA-NIAID-DAIT-NIHAI201800001](#)

Type:

Application Due Date: Sep 27, 2018 3:00 pm Eastern

Funding Opportunity Announcement: This program will support the identification of human B cell epitopes derived from pathogens or elicited by vaccines against pathogens, coupled with basic studies to understand protective immunity mediated by antibodies and, when applicable, pathological consequences of antibody responses; as well as the identification of human B cell epitopes derived from self-antigens, coupled with basic studies to understand the role of autoantibodies in autoimmune disease. Investigators may utilize recent technological advances for epitope discovery, such as high throughput single cell B cell analysis, or systems serology; or develop new or improved technologies, including computer-based B cell epitope prediction algorithms, for the identification of novel B cell epitopes. Epitope discovery methods may include basic studies in appropriate animal models, but human samples will be required to validate the epitope as a target of antibody-mediated protective immunity and to understand the mechanisms by which the antibodies induce immune protection or contribute to pathogenesis. Supported investigators will be required to attend an annual program review meeting at NIH and submit their epitope information to the Immune Epitope Database and Analysis Resource (www.iedb.org).

Contracts awarded in FY09 and in FY14 have been productive and minor changes are anticipated for the FY19 renewal. The renewed solicitation contains a programmatic emphasis on inclusion of mechanisms of antibody-mediated protection not explained by neutralization by antibody (e.g., antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis, and complement-dependent cytotoxicity) and for the first time includes the study of autoimmune responses and all transplantation. It is anticipated that three to five cost-reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about August 30, 2019.

Budget: NIAID estimates that the average annual total cost (direct and indirect costs combined) is \$1.0M per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five years.

3. 2018 NIAID Omnibus Broad Agency Announcement

Letter of Intent: Contract Specialist julie.rodriquez@nih.gov

Hyperlink: [HHS-NIH-NIAID-BAA2018](#)

Type:

Funding Opportunity Announcement: The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the **Division of Microbiology and Infectious Diseases (DMID)**, NIAID, NIH.

Research Area 001: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases. The objective of this Research Area is the development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of select pathogens, or in response to naturally-occurring outbreaks of infectious diseases caused by pathogens identified in this Research Area. Solicited products are anticipated to include: Antibacterial Therapeutics; Antiviral Therapeutics; and, Anti-toxin Therapeutics.

Research Area 002: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. The objective of this Research Area is the development of vaccines for scenarios associated with intentional release of a NIAID Category A, B, or C Priority Pathogen, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens or Zika virus (Zika virus vaccine would be included only as a component of a multivalent vaccine for other pathogens such as a vaccine for Flavivirus family). Solicited Products are anticipated to include: Technology Gaps that Slow Progression to Clinical Testing; Novel Vaccine "Plug-and-Play" Technologies; Enhanced Vaccine Performance (with special interest in simplicity and speed of delivery, rapid immune response and sterilizing immunity); and Vaccines Against Antimicrobial Resistance Threats.

Any responsible offeror may submit a proposal which shall be considered by the Agency. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website <https://ecps.nih.gov/NIAID> and then click on "How to Submit."

Budget: NIAID estimates that two or more awards may be issued for the Research Areas identified below, for a total estimated funding amount up to \$15.5 million for non-severable base contract work across all contracts (direct and indirect costs combined.) The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror should not exceed five (5) years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)